Document Detail

E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells.
MedLine Citation:
PMID:  12065845     Owner:  NLM     Status:  MEDLINE    
Pancreatic cancer is often resistant to conventional chemotherapy. In this study, we examined the role of adenovirus-mediated overexpression of E2F-1 in inducing apoptosis and increasing the sensitivity of pancreatic cancer cells to chemotherapeutic agents. MIA PaCa-2 pancreatic head exocrine adenocarcinoma cells (mutant p53) were treated by mock infection or adenoviruses expressing beta-galactosidase or E2F-1 (Ad-E2F-1) alone or in combination with sublethal concentrations of each chemotherapeutic drug. Cell growth and viability were assessed at selected time points. Apoptosis was evaluated by flow cytometry, characteristic changes in cell morphology and poly (ADP-ribose) polymerase (PARP) cleavage. Western blot analysis was used to examine the expression of E2F-1 and Bcl-2 family member proteins and PARP cleavage. Western blot analysis revealed marked overexpression of E2F-1 at a multiplicity of infection (MOI) of 20 and 70. By 3 days after infection, Ad-E2F-1 treatment at an MOI of 70 resulted in approximately a 20-fold reduction in cell growth and 60% reduction in cell viability as compared to mock-infected cells. Cell cycle analysis, PARP cleavage and changes in cell morphology supported apoptosis as the mechanism of cell death in response to E2F-1. In order to test the efficacy of treatment with a combination of gene therapy and chemotherapy, we utilized concentrations of Ad-E2F-1 which reduced viability to 50% in combination with each chemotherapeutic agent. Cotreatment of the cells with E2F-1 virus and roscovitine (ROS) or etoposide resulted in an additive effect on cell growth inhibition and induction of apoptosis. Interestingly, 5-fluorouracil did not cooperate with Ad-E2F-1 in the mediation of tumor death or inhibition of cell growth. Immunoblotting for Bcl-2 family members revealed no significant changes in the expression levels of Bcl-2, Bcl X(L), Bax or Bak following gene or 'chemogene' therapy with E2F-1. However, a Bax cleavage product was noted which was substantially increased by cotreatment with ROS or etoposide. E2F-1 overexpression initiates apoptosis and suppresses growth in pancreatic MIA PaCa-2 cells in vitro. E2F-1-mediated apoptosis was not associated with significant changes in the expression of Bcl-2 family member proteins in these pancreatic cancer cells. ROS and etoposide, when combined with E2F-1 overexpression, induce apoptosis in an additive manner. This chemogene combination may provide a potentially useful therapeutic strategy for advanced pancreatic cancer.
Mary Jane Elliott; Michael R Farmer; Cesar Atienza; Ariel Stilwell; Yan Bin Dong; Hai Liang Yang; Sandra L Wong; Kelly M McMasters
Related Documents :
9893125 - Bcl-2 overexpression prevents apoptosis-induced madin-darby canine kidney simple epithe...
10953095 - Dissecting affinity maturation: a model explaining selection of antibody-forming cells ...
11227215 - Bcl-2 protects neuronal cells against taxol-induced apoptosis by inducing multi-nucleat...
9187115 - Factors affecting topotecan-induced programmed cell death: adhesion protects cells from...
12734805 - Visualization of specific interaction between biomimetic glycopolymer containing reduci...
8712705 - Synthesis of ether-linked analogues of lysophosphatidate and their effect on the prolif...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine     Volume:  23     ISSN:  1010-4283     ISO Abbreviation:  Tumour Biol.     Publication Date:    2002 Mar-Apr
Date Detail:
Created Date:  2002-06-14     Completed Date:  2002-08-05     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8409922     Medline TA:  Tumour Biol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  76-86     Citation Subset:  IM    
Copyright Information:
Copyright 2002 S. Karger AG, Basel
Department of Surgery, University of Louisville, James Graham Brown Cancer Center, Louisville, KY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenoviruses, Human / genetics
Antimetabolites, Antineoplastic / pharmacology
Cell Cycle
Cell Cycle Proteins*
Cell Division / drug effects
Cyclin-Dependent Kinases / antagonists & inhibitors
DNA Replication / drug effects
DNA Topoisomerases, Type II / antagonists & inhibitors
DNA-Binding Proteins*
Drug Resistance, Neoplasm*
Drug Synergism
E2F Transcription Factors
E2F1 Transcription Factor
Enzyme Inhibitors / pharmacology
Etoposide / pharmacology
Fluorouracil / pharmacology
Gene Therapy*
Genetic Vectors / genetics
Neoplasm Proteins / antagonists & inhibitors
Pancreatic Neoplasms / pathology*,  therapy
Poly(ADP-ribose) Polymerases / metabolism
Purines / pharmacology
Recombinant Fusion Proteins / physiology
Transcription Factors / genetics,  physiology*
Tumor Cells, Cultured / drug effects,  pathology
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Cell Cycle Proteins; 0/DNA-Binding Proteins; 0/E2F Transcription Factors; 0/E2F1 Transcription Factor; 0/E2F1 protein, human; 0/Enzyme Inhibitors; 0/Neoplasm Proteins; 0/Purines; 0/Recombinant Fusion Proteins; 0/Transcription Factors; 0/roscovitine; 33419-42-0/Etoposide; 51-21-8/Fluorouracil; EC Polymerases; EC Kinases; EC Topoisomerases, Type II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the res...
Next Document:  Telomerase assay and HPV 16/18 typing as adjunct to conventional cytological cervical cancer screeni...